The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib is an emerging cancer
therapeutic that just recently gained Food and Drug Administration approval for treatment of …

Background Radiotherapy is the primary approach for nasopharyngeal carcinoma (NPC).
Although high survival rates can be obtained with radiation for early stage lesions, distant …

Recently developed potent and selective CDK4/6 inhibitors fall into two classes based on
structure and toxicity profiles in clinical studies. One class, exemplified by palbociclib and …

Cancer cells bypass normal controls over mitotic cell-cycle progression to achieve a
deregulated state of proliferation. The retinoblastoma tumor suppressor protein (pRb) …

Background: Dysregulation of the cyclin D-CDK4/6-Rb pathway is a frequent feature of ER
positive breast cancers and has been linked with endocrine resistance. Several randomised …

The use of CDK4/6 inhibitors in the treatment of a wide range of cancers is an area of
ongoing investigation. Despite their increasing clinical use, there is limited understanding of …

Background A cyclin-dependent kinase (CDK) 4/6 inhibitor, palbociclib, has been used to
treat patients with estrogen receptor (ER)-positive (+) and human epidermal growth factor …

Purpose: Ribociclib (an oral, highly specific cyclin-dependent kinase 4/6 inhibitor) inhibits
tumor growth in preclinical models with intact retinoblastoma protein (Rb+). This first-in …

An uncontrolled cell cycle is an obvious marker of tumor cells. The G1‑S phase is an
important restriction point in the normal cell cycle, but in cancer cells the restriction function …

The ability to sustain unscheduled proliferation is a hallmark of cancer. The normal process
of cell division occurs via the cell cycle, a series of highly regulated steps that are …